Your browser doesn't support javascript.
loading
Post-acute phase and sequelae management of epidermal necrolysis: an international, multidisciplinary DELPHI-based consensus.
Ingen-Housz-Oro, S; Schmidt, V; Ameri, M M; Abe, R; Brassard, A; Mostaghimi, A; Paller, A S; Romano, A; Didona, B; Kaffenberger, B H; Ben Said, B; Thong, B Y H; Ramsay, B; Brezinova, E; Milpied, B; Mortz, C G; Chu, C Y; Sotozono, C; Gueudry, J; Fortune, D G; Dridi, S M; Tartar, D; Do-Pham, G; Gabison, E; Phillips, E J; Lewis, F; Salavastru, C; Horvath, B; Dart, J; Setterfield, J; Newman, J; Schulz, J T; Delcampe, A; Brockow, K; Seminario-Vidal, L; Jörg, L; Watson, M P; Gonçalo, M; Lucas, M; Torres, M; Noe, M H; Hama, N; Shear, N H; O'Reilly, P; Wolkenstein, P; Romanelli, P; Dodiuk-Gad, R P; Micheletti, R G; Tiplica, G S; Sheridan, R.
Afiliação
  • Ingen-Housz-Oro S; Department of Dermatology, AP-HP, Henri Mondor Hospital, 1 Rue Gustave Eiffel, 94000, Créteil, France. saskia.oro@aphp.fr.
  • Schmidt V; ToxiTEN Group, European Reference Network for Rare Skin Diseases, Paris, France. saskia.oro@aphp.fr.
  • Ameri MM; Reference Center for Toxic Bullous Dermatoses and Severe Drug Reactions TOXIBUL, Créteil, France. saskia.oro@aphp.fr.
  • Abe R; EpiDermE, Université Paris Est Créteil, Créteil, France. saskia.oro@aphp.fr.
  • Brassard A; University Hospital Basel, Basel, Switzerland.
  • Mostaghimi A; Faculty of Medicine, University of Zurich, Zurich, Switzerland.
  • Paller AS; Faculty of Medicine, University of Zurich, Zurich, Switzerland. saskia.oro@aphp.fr.
  • Romano A; Department of Dermatology, University Hospital Zurich, Zurich, Switzerland. saskia.oro@aphp.fr.
  • Didona B; Christine Kühne-Center for Allergy Research and Education, Davos, Switzerland. saskia.oro@aphp.fr.
  • Kaffenberger BH; Division of Dermatology, Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan.
  • Ben Said B; Department of Dermatology, UC Davis Medical Center, Sacramento, CA, USA.
  • Thong BYH; Department of Dermatology, Brigham and Women's Hospital, Boston, MA, USA.
  • Ramsay B; Department of Dermatology, Northwestern University Feinberg School of Medicine, Chicago, IL, USA.
  • Brezinova E; Oasi Research Institute-IRCCS, Troina, Italy.
  • Milpied B; ToxiTEN Group, European Reference Network for Rare Skin Diseases, Paris, France.
  • Mortz CG; Rare Disease Unit, I Dermatology Division, Istituto Dermopatico Dell'Immacolata, IRCCS, Rome, Italy.
  • Chu CY; ToxiTEN Group, European Reference Network for Rare Skin Diseases, Paris, France.
  • Sotozono C; The Ohio State University Wexner Medical Center Division of Dermatology, Upper Arlington, OH, USA.
  • Gueudry J; ToxiTEN Group, European Reference Network for Rare Skin Diseases, Paris, France.
  • Fortune DG; Reference Center for Toxic Bullous Dermatoses and Severe Drug Reactions TOXIBUL, Créteil, France.
  • Dridi SM; Department of Dermatology, CHU Edouard Herriot, Lyon, France.
  • Tartar D; Department of Rheumatology, Allergy and Immunology, Tan Tock Seng Hospital, Singapore, Singapore.
  • Do-Pham G; Department of Dermatology, University Hospital Limerick, Limerick, Ireland.
  • Gabison E; ToxiTEN Group, European Reference Network for Rare Skin Diseases, Paris, France.
  • Phillips EJ; First Department of Dermatovenereology, Masaryk University Faculty of Medicine, St. Ann's Faculty Hospital in Brno, Brno, Czech Republic.
  • Lewis F; ToxiTEN Group, European Reference Network for Rare Skin Diseases, Paris, France.
  • Salavastru C; Reference Center for Toxic Bullous Dermatoses and Severe Drug Reactions TOXIBUL, Créteil, France.
  • Horvath B; Department of Adult and Pediatric Dermatology, Bordeaux University Hospitals, Bordeaux, France.
  • Dart J; Department of Dermatology and Allergy Center, Odense Research Center for Anaphylaxis (ORCA), Odense University Hospital, Odense, Denmark.
  • Setterfield J; Department of Dermatology, National Taiwan University Hospital, National Taiwan University College of Medicine, No. 7, Chung-Shan South Road, Taipei, 10002, Taiwan.
  • Newman J; Department of Ophthalmology, Kyoto Prefectural University of Medicine, 465 Kajii-Cho, Hirokoji-Agaru, Kawaramach-Dori, Kamigyo-Ku, Kyoto, 602-0841, Japan.
  • Schulz JT; Reference Center for Toxic Bullous Dermatoses and Severe Drug Reactions TOXIBUL, Créteil, France.
  • Delcampe A; Department of Ophthalmology, CHU Charles-Nicolle, Rouen, France.
  • Brockow K; Department of Psychology, University of Limerick, Limerick, Ireland.
  • Seminario-Vidal L; Reference Center for Toxic Bullous Dermatoses and Severe Drug Reactions TOXIBUL, Créteil, France.
  • Jörg L; MICORALIS Laboratory, Department of Periodontology, Faculty of Dentistry, Côte d'Azur University, Saint Roch Hospital, Nice, France.
  • Watson MP; Department of Dermatology, University of California Davis, Sacramento, CA, USA.
  • Gonçalo M; Reference Center for Toxic Bullous Dermatoses and Severe Drug Reactions TOXIBUL, Créteil, France.
  • Lucas M; Department of Internal Medicine, Centre Hospitalier Intercommunal de Créteil, Créteil, France.
  • Torres M; Fondation Ophtalmologique Adolphe de Rothschild, Paris, France.
  • Noe MH; Institute for Immunology and Infectious Diseases, Murdoch University, Murdoch, WA, Australia.
  • Hama N; Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, USA.
  • Shear NH; St John's Institute of Dermatology, Guy's and St Thomas' Hospital, London, UK.
  • O'Reilly P; ToxiTEN Group, European Reference Network for Rare Skin Diseases, Paris, France.
  • Wolkenstein P; Department of Paediatric Dermatology, Colentina Clinical Hospital, Carol Davila University of Medicine and Pharmacy, Bucharest, Romania.
  • Romanelli P; ToxiTEN Group, European Reference Network for Rare Skin Diseases, Paris, France.
  • Dodiuk-Gad RP; Department of Dermatology, University Medical Center Groningen, University of Groningen, Hanzeplein 1, 9700 RB, Groningen, The Netherlands.
  • Micheletti RG; Moorfields Eye Hospital NHS Foundation Trust, The UCL Institute of Ophthalmology, London, UK.
  • Tiplica GS; ToxiTEN Group, European Reference Network for Rare Skin Diseases, Paris, France.
  • Sheridan R; Department of Oral Medicine, Guy's and St Thomas' NHS Foundation Trust, London, UK.
Orphanet J Rare Dis ; 18(1): 33, 2023 02 22.
Article em En | MEDLINE | ID: mdl-36814255
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Síndrome de Stevens-Johnson Idioma: En Ano de publicação: 2023 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Síndrome de Stevens-Johnson Idioma: En Ano de publicação: 2023 Tipo de documento: Article